Description
The role of PARP inhibitors in the repair process of renal remains unclear. The effects of JPI-289, a novel PARP inhibitor, during the healing phase after renal ischemia-reperfusion injury were investigated.
Overall Design
scRNAseq were perfomed with post-ischemic kidneys. JPI-289 100 mg/kg (n = 1) or saline (n = 1) was injected into the peritoneal cavity immediately before reperfusion during bilateral renal ischemia-reperfusion surgery. Mice were sacrificed at 24 h following bilateral ischemia-reperfusion surgery
Curator
yq_pan